Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep 20:16:994.
doi: 10.1186/s12889-016-3671-z.

Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals

Zachary C Rich  1 , Carissa Chu  1   2 , Jessica Mao  1 , Kali Zhou  1 , Weiping Cai  3 , Qingyan Ma  1 , Paul Volberding  2 , Joseph D Tucker  4   5
Affiliations

Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals

Zachary C Rich et al. BMC Public Health. .

Abstract

Background: While the public health benefits of new HCV treatments depend on treatment adherence, particularly among people who inject drugs (PWID), several social and medical factors can jeopardize treatment adherence. The aim of this study is to examine the qualitative literature on facilitators to HCV treatment adherence among PWID.

Methods: We searched six databases to identify qualitative research studies on HCV treatment adherence facilitators among PWID. Two reviewers independently extracted and analyzed data using PRISMA guidelines and the CASP tool to evaluate study quality.

Results: From ten studies representing data from 525 participants, three major themes emerged across studies: logistical facilitators within health systems enhanced HCV treatment adherence, positive social interactions between PWID and staff provided positive feedback during treatment, and HCV treatment may complicate the addiction recovery process.

Conclusions: Although PWID face several barriers to adherence, we identified treatment adherence facilitators that could be incorporated into clinical practice.

Keywords: Hepatitis C virus; Injection drug use; Treatment adherence.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flowchart demonstrating search strategy
See this image and copyright information in PMC

References

    1. Hepatitis C. Fact Sheet N0 164 [http://www.who.int/mediacentre/factsheets/fs164/en/]. Accessed 17 Sept 2016.
    1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–38. doi: 10.1016/j.jhep.2006.05.013. - DOI - PubMed
    1. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4):271–8. doi: 10.7326/0003-4819-156-4-201202210-00004. - DOI - PubMed
    1. Graham CS, Swan T. A path to eradication of hepatitis C in low- and middle-income countries. Antivir Res. 2015;119:89–96. doi: 10.1016/j.antiviral.2015.01.004. - DOI - PubMed
    1. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571–83. doi: 10.1016/S0140-6736(11)61097-0. - DOI - PMC - PubMed

Publication types

Substances